Michael Wolfe

Director de Operaciones en Switch Therapeutics, Inc. .

Health Technology

Consumer Services

Cargos activos de Michael Wolfe

Empresas	Cargo	Inicio	Fin
Switch Therapeutics, Inc. Switch Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Switch Therapeutics, Inc. is an American biotechnology company that aims to treat a range of diseases affecting the central nervous system and systemic indications with significant unmet need. Switch is based in , and was founded by Dee Datta, who has been the CEO since incorporation. The company is pioneering a new type of medicine that integrates nucleic acid nanotechnology and RNA interference (RNAi) science. The company's novel gene knockdown approach, the Conditionally Activated siRNA (CASI) platform, is based on technology developed by renowned researchers in the field of RNA and drug development from Caltech, Harvard Medical School, and City of Hope.	Director de Operaciones	28/03/2023	-

Empresas	Cargo	Inicio	Fin
KEZAR LIFE SCIENCES, INC.	Director de Operaciones	-	01/01/2023
Onyx Pharmaceuticals, Inc. Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA.	Corporate Officer/Principal	01/10/2010	01/01/2014

California Polytechnic State University (San Luis Obispo)

Undergraduate Degree

Internacional

Estados Unidos

Operativa

Chief Operating Officer	2
Corporate Officer/Principal	1
Undergraduate Degree	1

Sectorial

Health Technology	4
Consumer Services	2

Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Empresas cotizadas	1
KEZAR LIFE SCIENCES, INC.	Health Technology

Empresas privadas	2
Onyx Pharmaceuticals, Inc. Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA.	Health Technology
Switch Therapeutics, Inc. Switch Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Switch Therapeutics, Inc. is an American biotechnology company that aims to treat a range of diseases affecting the central nervous system and systemic indications with significant unmet need. Switch is based in , and was founded by Dee Datta, who has been the CEO since incorporation. The company is pioneering a new type of medicine that integrates nucleic acid nanotechnology and RNA interference (RNAi) science. The company's novel gene knockdown approach, the Conditionally Activated siRNA (CASI) platform, is based on technology developed by renowned researchers in the field of RNA and drug development from Caltech, Harvard Medical School, and City of Hope.	Health Technology

Empresas privadas

Health Technology